secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2022-02-17T23:59:59+00:00
Accession:  0001628280-22-002935
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma reports record FY2021 sales $2.832B (+32%), guides FY2022 EPS $9.20-$9.35
--------------------------------------------------------------------------------

- Q4 net sales $730.8M (+26%), organic +28.3%; full-year sales $2.832B (+31.9%), organic +29.4%.
- Full-year reported diluted EPS $8.67 (+90%); adjusted diluted EPS $8.58 (+80%).
- Proprietary Products segment Q4 sales $609.3M (+34.2%), driven by high-value product growth across all market units.
- FY2022 guidance: net sales $3.050-$3.075B (~10% organic growth), reported EPS $9.20-$9.35, capex $380M.
- Operating cash flow $584M (+23.6%), free cash flow $330.6M (+10.9%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000162828022002935/0001628280-22-002935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000162828022002935/wst-20220217.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-002935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer